However, when analyzing molecular subtypes within the AML study cohort, several AML-subtypes show worse prognosis with high MEN1 expression, including NPM1-mutated, which has been shown to be sensitive to MEN1 inhibition [22,23] (Supplementary Figure S1A). The gene discussed is MEN1; the disease is acute myeloid leukemia.